0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
87 Ansichten7 Seiten
As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug designers and marketers. The injectable device sector today consists of a half-dozen established device classes and two emerging classes. For the remainder of the decade, pipeline drugs and shifting demographics will drive sector growth as an aging population of baby boomers (23% of U.S. population) provides stimulus for industry demand. Currently, the over 65 segment accounts for approximately 13% of the U.S. population, with an estimated 40% of total healthcare expenditures, but by 2020, this segment is expected to grow to 17% of the population. This aging of the population will predominately benefit products that can be used by the elderly.This report examines the key therapeutic, product, market and regulatory factors for injection devices, providing essential insight and forecasts into the implications of this evolving landscape.
As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug designers and marketers. The injectable device sector today consists of a half-dozen established device classes and two emerging classes. For the remainder of the decade, pipeline drugs and shifting demographics will drive sector growth as an aging population of baby boomers (23% of U.S. population) provides stimulus for industry demand. Currently, the over 65 segment accounts for approximately 13% of the U.S. population, with an estimated 40% of total healthcare expenditures, but by 2020, this segment is expected to grow to 17% of the population. This aging of the population will predominately benefit products that can be used by the elderly.This report examines the key therapeutic, product, market and regulatory factors for injection devices, providing essential insight and forecasts into the implications of this evolving landscape.
As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug designers and marketers. The injectable device sector today consists of a half-dozen established device classes and two emerging classes. For the remainder of the decade, pipeline drugs and shifting demographics will drive sector growth as an aging population of baby boomers (23% of U.S. population) provides stimulus for industry demand. Currently, the over 65 segment accounts for approximately 13% of the U.S. population, with an estimated 40% of total healthcare expenditures, but by 2020, this segment is expected to grow to 17% of the population. This aging of the population will predominately benefit products that can be used by the elderly.This report examines the key therapeutic, product, market and regulatory factors for injection devices, providing essential insight and forecasts into the implications of this evolving landscape.
Report Prospectus Life Science Technology Practice A Comprehensive Report
Greystone Research Associates is pleased to announce the publication of a new market study. Drug Injection Devices to 2020: Devices, Products, Markets, Strategies and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, drug classes, disease segments, and product selection criteria for drug injection devices. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The Evolving Landscape for Injectable Drugs As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug designers and marketers. The injectable device sector today consists of a half-dozen established device classes and two emerging classes. For the remainder of the decade, pipeline drugs and shifting demographics will drive sector growth as an aging population of baby boomers (23% of U.S. population) provides stimulus for industry demand. Currently, the over 65 segment accounts for approximately 13% of the U.S. population, with an estimated 40% of total healthcare expenditures, but by 2020, this segment is expected to grow to 17% of the population. This aging of the population will predominately benefit products that can be used by the elderly.
Report Value Chain Who Should Read This Report
Development Drug Developers Device Suppliers CMOs Components/APIs Testing/Validation Clinical Trial Mgmt
Industry Pharma Managers Biotech Managers Drug Marketers Industry Strategists Financial Analysts Management Consultants Market Clinical Managers Drug Distributors Pharma Regulators FDA Consultants Managed Care Managers
D r u g
I n j e c t i o n
D e v i c e s
t o
2 0 2 0
Executive Summary Drug Injection Device Market Dynamics Evolution in Injectable Drug Development Injectable Drug Demand Drivers Diseases and Indications Syringe Economics Chronic Conditions & Self-Administration Technology Factors Device Selection Factors Market Segmentation Product Features & Ease of Use Competitive Landscape Injection Device Suppliers Capabilities and Market Presence Technology and Infrastructure Market Success Factors Injection Devices Autoinjectors Dual Chamber Syringes Needle-free Injectors Pen Injectors Prefilled Syringes Safety Syringes Emerging Device Classes Wearable Injectors Patch Pumps Large Volume wearable Injectors Risks and Opportunities Injection Device Selection Criteria Stability and Material Selection Issues Single vs Multi-Dose Devices Fixed vs Variable Dose Devices Lyophilized Drugs/Reconstitution Syringe Safety/Sharps Protection Needle Configuration Strategies Disposable Drug Cartridges Human Engineering/Ergonomics Branding/Private Labeling Drug Delivery Devices Device Classes and Analysis Autoinjectors Autoinjector Device Categories Reusable Autoinjectors Disposable Autoinjectors Product Specific Autoinjectors Autoinjector-specific Selection Factors Safety Features Needle Shielding Needle Insertion Depth Failsafe Activation Dose Inspection/Injection Confirmation Device Evolution and Market Impact Dual Chamber Syringes Needle-free Injectors Device Categories End User/Practitioner/Mass Immunization Injectors Prefilled Disposable Models Refillable Cartridge Designs Needle-free Injector-specific Selection Factors Table of Contents
Energy Source/Injection Site Selection Injection Site Selection Needle-free Injectors the Next Six Years Pen Injectors Recent Segment Evolution and Product Consolidation Pen Design and Device Selection Standardized Pen Platforms Custom Pen Designs Pen Classes Reusable Pens Disposable Pens Dual Chamber Pens Pen Injector Evolution the Picture in 2020 Prefilled Syringes Prefilled Syringe Device Categories Glass Prefilled Syringes Plastic Prefilled Syringes Prefillable Safety Syringes Prefilled Syringe Selection Factors Ready to Fill Prefillable Syringes Fill-and-Finish CSO Selection PFS Trending and Evolution the Next Six Years Safety Syringes Safety Syringe Device Categories Integrated Safety Syringes Automatic Safety Mechanism Manual Safety Mechanism Post Manufacture Add-on/Bolt-on Safety Mechanisms Safety Syringes Market Evolution and Segment Expectations Wearable Injectors Patch Pumps Large Volume Wearable Injectors Drug Injection Device Market Segment Analysis & Forecasts Anaphylaxis Anticoagulants Antivirals Autoimmune Diseases Diabetes Emergency Medicine Hematopoietics Hormone Replacement Neurology Osteoporosis Reproductive Health Vaccines Injectable Drug Therapeutics - Market Factors Regulatory Factors and Issues FDA Regulations Regulating Combination Products Sharps Legislations Growth and Diversity of Safety Syringes Sharps Disposal Managed Care and Healthcare Economics Company Profiles
Go to http://www.greystoneassociates.org/Drug_Delivery.htm for more information
Detailed Quantitative Market Data Over 80 Charts & Tables Go to http://www.greystoneassociates.org/Drug_Delivery.htm for more information
What You Will Learn
Analyzes and evaluates the shifting landscape for injectable drug delivery and assesses the market impact of new and evolving syringes and injectors therapeutic indication Assesses syringe and injector device designs, feature/functionality, product branding, competing technologies and market development issues Provides detailed descriptions of key injection device market segments, market demographics, and business strategies Forecasts syringe and injector demand by indication and therapy to 2020 Profiles leading injection device companies, their product development activities, business strategies, and corporate alliances and affiliations Evaluates the impact of economic, technology, and regulatory factors on injectable drug delivery demand
Report Format and Availability
This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.
Methodology
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations. Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets. Comprehensive Assessments & Forecasts Go to http://www.greystoneassociates.org/Drug_Delivery.htm for more information
Ordering Information
Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US. Payment We accept the following forms of payment: Company Check: Please make checks payable to Greystone Associates Credit Cards: We accept MasterCard, Visa and American Express Wire Transfers: See Wire Transfers below for more information Orders Outside the U.S. Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a $50 per copy shipping and handling charge for international shipments.
Wire Transfers: TD Banknorth 300 Franklin Street Manchester, NH 03103 (Call for Account Information) Mailing Address: Greystone Research Associates Client Services P.O. Box 1362 Amherst, NH 03031
Drug Injection Devices to 2020 Devices, Products, Markets, Strategies & Forecasts Select Format Price (U.S. funds) Total
Electronic $4,850.00
Site License $7,500.00
Enterprise License $9,500.00
Total Payment (U.S. funds) Method of Payment: ___ Company Check ___ ___ ___ ___ Wire Transfer (International) Card Number:___________________________ Name on Card ________________________________________
Billing Information Shipping Information Click here if same as Billing Information Name: Name: Title: Title: Company: Company: Street Address: Street Address: City,State/Province: City,State/Province: Country/Postal Code: Country/Postal Code: Phone: Phone: Fax: Fax: Email: Email:
How To Order Fax to: 603-218-7020 or email to clientservices@greystoneassociates.org